BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (A...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Stintzing
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors S. Stintzing1, L. Fischer von Weikersthal2, T. Decker3, A. Kiani4, U. Vehling-Kaiser5, S.-. Al-Batran6, T. Heintges7, C. Lerchenmüller8, C. Kahl9, G. Seipelt10, F. Kullmann11, M. Stauch12, J. Hielscher13, M. Lerch14, W. Scheithauer15, A. Jagenburg16, S. Held17, D. Modest18, A. Jung19, T. Kirchner19, V. Heinemann20
  • 1Department of Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU, Munich, Germany, /
  • 2Department of Oncology, Gesundheitszentrum St. Marien GmbH, Amberg, Germany, /
  • 3Onkologie Ravensburg, Germany, Ravensburg, Germany, /
  • 4Klinik Herzoghöhe, Bayreuth, Germany, /
  • 5Onkologische Praxis, Landshut, Germany, /
  • 6Krankenhaus Nordwest, Frankfurt, Germany, /
  • 7Department of Medicine II, Städtisches Klinikum Neuss, Germany, Neuss, Germany, /
  • 8Schwerpunktpraxis Onkologie und Hämatologie, Münster, Germany, /
  • 9Haematology and Oncology, Staedtisches Klinikum Magdeburg, Magdeburg, Germany, /
  • 10Onkologische Praxis, Bad Soden, Germany, /
  • 11Department of Medicine I, Klinikum Weiden, Weiden, Germany, /
  • 12Onkologische Praxis, Kronach, Germany, /
  • 13Chirurgische Klinik, Chemnitz gGmbH, Chirurgische Onkologie, Chemnitz, Germany, /
  • 14Department of Internal Medicine A, University Hospital Greifswald, Greifswald, Germany, /
  • 15Medizinische Universität Wien, Vienna, Austria, /
  • 16Radiology Consulting GmbH, Leverkusen, Germany, /
  • 17Clinassess, Leverkusen, Germany, /
  • 18Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany, /
  • 19Department of Pathology, Ludwig-Maximilians University of Munich, Munich, Germany, /
  • 20Comprehensive Cancer Center, Krebszentrum München, München, Germany, /

Abstract

The FIRE-3 study (AIO KRK-0306) was initiated as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) to FOLFIRI plus bevacizumab (bev) as first-line treatment in mCRC patients. FOLFIRI plus cet as first-line treatment of KRAS WT mCRC patients resulted in comparable overall response rates (ORR) and progression free survival (PFS) when compared to FOLFIRI plus bev. But overall survival (OS) was significantly longer in the FOLFIRI plus cet arm. Here we investigated if there are also biomarkers predicting outcome for both the RAS- or BRAF mutated subgroups of FIRE-3.